Rapport Therapeutics (RAPP) Capital Expenditures (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Capital Expenditures for 4 consecutive years, with $86000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures fell 70.45% year-over-year to $86000.0; the TTM figure through Mar 2026 stood at $411000.0 (down 74.69% YoY), while the FY2025 annual figure was $616000.0, down 74.39% from the prior year.
• Capital Expenditures eased to $86000.0 in Q1 2026 per RAPP's latest filing, from $169000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.4 million in Q4 2023 and bottomed at $22000.0 in Q2 2025.
• Historically, Capital Expenditures has averaged $417818.2 across 4 years, with a median of $169000.0 in 2025.
• Annual changes were most pronounced in 2024 — Capital Expenditures surged 169.23% — and 2025, when it slumped 97.72%.
• Rapport Therapeutics' Capital Expenditures stood at $1.4 million in 2023, then plunged by 84.27% to $226000.0 in 2024, then slipped by 25.22% to $169000.0 in 2025, then tumbled by 49.11% to $86000.0 in 2026.
• Business Quant data shows RAPP's Capital Expenditures at $86000.0 in Q1 2026, $169000.0 in Q4 2025, and $134000.0 in Q3 2025.